About
Technology
Issues
FAQ
Links
Official Page
TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.